Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

5.05USD
24 Mar 2017
Change (% chg)

$0.15 (+3.06%)
Prev Close
$4.90
Open
$4.90
Day's High
$5.05
Day's Low
$4.85
Volume
2,241
Avg. Vol
9,352
52-wk High
$8.17
52-wk Low
$3.81

Latest Key Developments (Source: Significant Developments)

Sphera Funds reports 6.17 pct passive stake in Aldeyra Therapeutics as of Feb 14
Tuesday, 21 Feb 2017 06:20am EST 

Aldeyra Therapeutics Inc :Sphera Funds Management Ltd reports 6.17 percent passive stake in Aldeyra Therapeutics Inc as of Feb 14 - sec filing.  Full Article

Aldeyra Therapeutics announces patient enrollment in conjunctivitis trial
Tuesday, 7 Feb 2017 08:00am EST 

Aldeyra Therapeutics Inc :Aldeyra therapeutics announces first patient enrolled in allergic conjunctivitis phase 2b clinical trial.  Full Article

Aldeyra Therapeutics Q3 loss per share $0.38
Monday, 14 Nov 2016 07:30am EST 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics Inc - Phase III vehicle-controlled trial in noninfectious anterior uveitis, expected to be initiated in first half of 2017 . Q3 loss per share $0.38 . Aldeyra therapeutics announces third quarter 2016 financial results .Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Aldeyra Therapeutics reports Q2 loss per share $0.41
Wednesday, 10 Aug 2016 07:00am EDT 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics announces second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.41 .Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.  Full Article

Aldeyra Therapeutics proposes public offering of common stock
Wednesday, 25 May 2016 04:01pm EDT 

Aldeyra Therapeutics : Aldeyra Therapeutics Inc proposes public offering of common stock .Net proceeds to be used for continued development of NS2 and other product candidates, including further clinical testing of NS2.  Full Article

Aldeyra Therapeutics announces positive results from Phase II clinical trials
Monday, 9 May 2016 07:30am EDT 

Aldeyra Therapeutics Inc : NS2 generally well tolerated; no serious adverse events, consistent with previous Phase I and Phase II clinical trials . No statistical differences among all groups in any clinical endpoint, including anterior chamber cell count and ocular flare . Aldeyra therapeutics announces positive results from phase II clinical trial in subjects with noninfectious anterior uveitis .Quarterly loss per share $0.51.  Full Article

Aldeyra Therapeutics announces closing of common stock offering
Friday, 22 May 2015 04:15pm EDT 

Aldeyra Therapeutics Inc:Announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised their option to purchase additional shares of common stock from Aldeyra.Underwriters purchased 122,500 additional shares from Aldeyra at the public offering price of $7.50 per share, less underwriting discounts and commissions.Net proceeds to Aldeyra from the offering, including the sale of the additional shares, were about $19.9 million, after deducting underwriting discounts and commissions.  Full Article

Aldeyra Therapeutics Inc announces pricing of follow-on public offering of common stock
Friday, 8 May 2015 08:01am EDT 

Aldeyra Therapeutics Inc:Prices its follow-on public offering of 2,700,000 shares of its common stock at $7.50 per share.Grants the underwriters a 30-day option to purchase up to an additional 405,000 shares of common stock.Expects to close the offering on or about May 13.Cowen and Company, LLC and Canaccord Genuity Inc. are acting as joint book-running managers and Janney Montgomery Scott LLC and Laidlaw & Company (UK) Ltd. are acting as co-managers for the offering.  Full Article

More From Around the Web

BRIEF-Aldeyra Therapeutics launches aldeyra registry for patients with Sjögren-Larsson syndrome

* Aldeyra Therapeutics launches the aldeyra registry for patients with Sjögren-Larsson syndrome Source text for Eikon: Further company coverage: